These findings demonstrate that by reprogramming tumor-specific T-cell responses to TGF-β, bispecific IL-13Rα2/TGF-β CAR-T cells can counter and remodel the immunosuppressive TME, driving potent anti-tumor responses in GBM (55). The gene discussed is IL13RA2; the disease is neoplasm.